Calliditas Therapeutics AB (publ) (CALT)

NASDAQ: CALT · Real-Time Price · USD
40.00
-0.04 (-0.10%)
Sep 20, 2024, 4:00 PM EDT - Market closed
133.37%
Market Cap 1.10B
Revenue (ttm) 151.09M
Net Income (ttm) -45.32M
Shares Out 54.01M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE 24.69
Dividend n/a
Ex-Dividend Date n/a
Volume 9,795
Open 40.00
Previous Close 40.04
Day's Range 40.00 - 43.00
52-Week Range 15.25 - 43.00
Beta 1.46
Analysts Hold
Price Target 41.40 (+3.5%)
Earnings Date Nov 11, 2024

About CALT

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 5, 2020
Employees 217
Stock Exchange NASDAQ
Ticker Symbol CALT
Full Company Profile

Financial Performance

In 2023, CALT's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.

Financial numbers in SEK Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CALT stock is "Hold." The 12-month stock price forecast is $41.4, which is an increase of 3.50% from the latest price.

Price Target
$41.4
(3.50% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

STOCKHOLM , Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm.

21 days ago - PRNewsWire

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg.

4 weeks ago - PRNewsWire

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

STOCKHOLM , Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of ...

4 weeks ago - PRNewsWire

Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Renée Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - Pr...

7 weeks ago - Seeking Alpha

Calliditas Interim Report January to June 2024

STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which...

7 weeks ago - PRNewsWire

Number of shares and votes in Calliditas Therapeutics

STOCKHOLM , July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the company's long-term inc...

2 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...

2 months ago - Accesswire

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Commission has granted a full marketing au...

2 months ago - PRNewsWire

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showin...

2 months ago - PRNewsWire

Launch of Phase 3 clinical trial with Nefecon in Japan

STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initia...

3 months ago - PRNewsWire

Calliditas provides setanaxib patent update

STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) ...

3 months ago - PRNewsWire

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM , June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Ad...

4 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of Shareholders

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...

Other symbols: AKLI
4 months ago - GlobeNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breach...

Other symbols: AKLI
4 months ago - Accesswire

SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate MODN, CALT

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breach...

Other symbols: MODN
4 months ago - Accesswire

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

STOCKHOLM , May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the Committee for Medicinal Products for Human Use (CH...

4 months ago - PRNewsWire

Calliditas Therapeutics' stock surges after $1.1 billion takeover bid

Calliditas Therapeutics AB's American depositary receipts CALT, -1.45% jumped more than 70% premarket on Tuesday after a nearly $1.1 billion takeover bid from Japanese conglomerate Asahi Kasei.

4 months ago - Market Watch

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

STOCKHOLM , May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nef...

4 months ago - PRNewsWire

Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Corp. (TOKYO:3407) today announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the p...

4 months ago - Business Wire

Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion

Japan's Asahi Kasei said on Tuesday it offered to acquire Calliditas Therapeutics for about 11.8 billion Swedish crowns ($1.1 billion) as part of a plan to become a global drug company.

4 months ago - Reuters

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

STOCKHOLM , May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (" ADS ") of...

4 months ago - PRNewsWire

Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q1 2024 Earnings Conference Call May 23, 2024 8:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - Presi...

4 months ago - Seeking Alpha

Calliditas Q1 report, January - March 2024

STOCKHOLM , May 23, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALTX) (STOCKHOLM: CALTX): Target market expansion following full approval in the US JANUARY - MARCH 2024 (COMPARED TO JANU...

4 months ago - PRNewsWire

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

STOCKHOLM , May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day on Thursd...

5 months ago - PRNewsWire

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

STOCKHOLM , May 15, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) ("Calliditas"), today announced upcoming data presentations and a sponsored symposium at th...

5 months ago - PRNewsWire